The clinical application of immunotherapy is the milestone of cancer treatment. However,
some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in …

While chemotherapy provides useful palliation, advanced lung cancer remains incurable
since those tumors that are initially sensitive to therapy rapidly develop acquired resistance …

Purpose Increased expression of eicosanoids in cancer has been associated with adverse
prognosis. We performed a randomized phase II trial to test the hypothesis that inhibitors of …

Lung carcinogenesis is a complex process involving the acquisition of genetic mutations that
confer cancer development and the malignant phenotype, and is critically linked to …

The purpose of this meta-analysis was to evaluate the efficacy and safety of celecoxib, a
selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy …

Background The addition of cyclo-oxygenase-2 (COX-2) inhibitors and prolonged constant
infusion (PCI) of gemcitabine to treatment for advanced non-small-cell lung cancer (NSCLC) …

Over the past decade, a multitude of targeted agents have been explored in the treatment of
advanced non–small cell lung cancer (NSCLC). Thus far, two broad classes of agents have …

Abstract Purpose: Cyclooxygenase (COX)-2 up-regulation plays an important role in the
pathogenesis of lung cancer. Selective COX-2 inhibitors have promoted chemosensitivity …

Background Inflammation is closely related to cancer prognosis. The effect of celecoxib, a
nonsteroidal anti‐inflammatory drug, on the prognosis of patients with cancer remains …

Lung cancer is the leading cause of cancer deaths world-wide. Recent advances in cancer
biology have led to the identification of new targets in neoplastic cells and the development …